Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Spyre Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 198 | 2 | 265 | +69 |
| Shares | 82.7M | 1.66M | 95.8M | +14.8M (+18.3%) |
| Value | $4.16B | $83.7M | $8.52B | +$4.44B (+108.8%) |
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (91)
Institutions that held Spyre Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (22)
Institutions that held Spyre Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Fairmount Funds Management LLC | 4,018,101 | $202.7M |
| Ra Capital Management, L.P. | 1,621,620 | $81.8M |
| Baker Bros. Advisors LP | 1,000,000 | $50.4M |
| Caligan Partners LP | 878,127 | $44.3M |
| ExodusPoint Capital Management, LP | 87,065 | $4.39M |
| Alps Advisors Inc | 63,939 | $3.23M |
| Assenagon Asset Management S.A. | 18,647 | $940.6K |
| Carlyle Group Inc. | 9,620 | $485.2K |
| RWC Asset Management LLP | 8,166 | $411.9K |
| Capstone Investment Advisors, LLC | 7,537 | $380.2K |
| Scientech Research LLC | 7,088 | $357.5K |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 6,140 | $309.7K |
| DeepCurrents Investment Group LLC | 4,740 | $239.1K |
| ABS Direct Equity Fund LLC | 2,800 | $193.6K |
| Patient Square Capital LP | 1,000 | $50.4K |
| Group One Trading, L.P. | 901 | $45.4K |
| Clear Street Markets LLC | 562 | $28.3K |
| Delos Wealth Advisors, LLC | 250 | $12.6K |
| Quadrant Capital Group LLC | 146 | $7.37K |
| MAI Capital Management | 13 | $656 |
| Massmutual Trust Co FSB | 3 | $151 |
| Twin Peaks Wealth Advisors, LLC | 3 | $151 |
Not filed for Q2 2026 yet (2)
Institutions that held Spyre Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Janus Henderson Group PLC | 1,656,164 | $83.6M |
| CWM, LLC | 2,105 | $106.2K |